A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 210
- Primary Endpoint
- Solicited adverse event rates (including injection site and systemic reactions)
Study Overview
Brief Summary
The purpose of this Phase II study is to provide data regarding the safety and immunogenicity for a range of dose levels of MEDI-517 in women who are HPV-16/18 seronegative and negative for high-risk HPV DNA. The study is designed to evaluate safety and immunogenicity data for MEDI-517 when formulated with either AS04 or aluminum hydroxide. Extended follow-up will provide long-term immune response data.
This study was originally performed by MedImmune. However, GSK is now responsible for the clinical development of the HPV vaccine.
Detailed Description
This is a Phase II double-blind, randomized, dose-comparison, multicenter study in the United States of three different dose levels of MEDI-517 (HPV-16/18 VLP AS04 vaccine) and one dose of MEDI-517 formulated with aluminum hydroxide, with doses administered at 0, 30 and 180 days. Healthy female volunteers 18 through 30 years of age will be entered into 4 treatment arms. The objectives of study are to evaluate reactogenicity, safety and immunogenicity.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 30 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Females 18 through 30 years of age (must not have reached the 31st birthday)
- •Unless previously surgically sterilized, agrees to use an effective method of birth control beginning 30 days before the first study injection and continuing through 60 days after the final study injection
- •Healthy by medical history and physical examination
- •Seronegative for HPV-16 and HPV-18 antibody by ELISA within 21 days of study entry
- •Cervical specimen negative for high-risk HPV DNA using the Digene Hybrid Capture® II HPV test (high-risk types Probe B) within 21 days of study entry
- •Normal Pap smear, using the Cytyc ThinPrep® Pap Test, within 21 days of study entry
- •No evidence of anogenital HPV lesions or no physical findings suggestive of other gynecologic pathogens on pelvic examination within 21 days of study entry
- •Agrees to no other experimental therapy or vaccines until 30 days after the last study injection
- •Written informed consent obtained from the volunteer
Exclusion Criteria
- •Acute illness or fever (oral temperature ≥ 99.5°F [37.5°C]) at start of the study
- •History or clinical manifestations of significant medical or psychiatric disorder
- •Pregnant or lactating
- •Use of immunosuppressive medication within the previous 90 days or history of immunodeficiency
- •History of cancer
- •History of alcohol or drug abuse within the past 2 years
- •Abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant
- •Receipt of immunoglobulin or blood products within 90 days prior to study entry
- •History of abnormal Pap smear (other than a single prior report of ASCUS or indeterminate Pap smear with a subsequent normal report)
- •Positive tests for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 antibody
- •Any prior receipt of any vaccine (experimental or otherwise) for treatment or prophylaxis of genital warts or other papillomavirus related condition. Any treatment of genital warts or other papillomavirus related condition within 6 months of randomization (local therapy for common skin and/or plantar warts is allowed)
- •Previous administration of any components of the investigational vaccine
- •Receipt of any experimental vaccine within 90 days prior to entry into this study
- •Receipt of any experimental drug therapy within 30 days or five half-lives of the experimental drug (if the half-life is known), whichever is longer
Arms & Interventions
Group C
Formulation 3 of the vaccine
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3) (Biological)
Group A
Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1) (Biological)
Group B
Formulation 2 of the vaccine
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2) (Biological)
Group D
Formulation 4 of the vaccine [with Al(OH)3]
Intervention: MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4) (Biological)
Outcomes
Primary Outcomes
Solicited adverse event rates (including injection site and systemic reactions)
Time Frame: For 7 days after each injection
Unsolicited adverse event rates
Time Frame: For 30 days after each injection
Serum ELISA titers against HPV-16 and HPV-18
Time Frame: 30 days after the third injection
Serious adverse event rates
Time Frame: From first injection through 30 days after last injection
Laboratory assessments (Biochemistry and Hematology parameters)
Time Frame: Study Days 0, 30 and 210
Vital signs (temperature, blood pressure, pulse rate, respiratory rate)
Time Frame: At the time of injection and 30 minutes after the injection
Secondary Outcomes
- Cervical and vaginal ELISA titers against HPV-16 and HPV-18(At Study Days 210 and 360)
- Cell-mediated immunity by IL-5, IFN-γ and lymphoproliferative assays(Study Days 0, 60, 210, and 360)
- Serum ELISA titers against HPV-16 and HPV-18(Study Days 0, 7, 30, 60, 180, 210, and 360, and at 24, 36, and 48 months)
- Neutralization titers against HPV-16 and HPV-18(Study Days 0, 60, 210 and 360)
- HPV-16 and HPV-18 ELISA and inhibitory ELISA(Study Days 0, 60, 210, and 360, and at 18, 24, 36, and 48 months)